丹蒌片联合比索洛尔治疗冠心病心绞痛的临床研究
|
摘要
目的探讨丹蒌片联合比索洛尔治疗冠心病心绞痛的临床疗效。方法选取2015年2月—2018年2月于天津市第三中心医院收治的冠心病心绞痛患者104例作为研究对象,随机分成对照组和治疗组,每组各52例。对照组口服富马酸比索洛尔片,1片/次,1次/d。治疗组患者在对照组治疗基础上口服丹蒌片,5片/次,3次/d。两组均连续治疗6周。观察两组患者的临床疗效标准和心电图疗效,比较两组患者ADL评分、硝酸甘油用量、颈动脉内中膜厚度(IMT值)、血清指标的变化情况。结果治疗后,对照组和治疗组的临床总有效率分别是76.92%、92.31%;心电图总有效率分别是82.69%、96.15%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者ADL评分均显著升高,而硝酸甘油用量及颈动脉IMT值均显著降低,同组治疗前后比较差异有统计学意义(P<0.05);治疗后,治疗组ADL评分显著高于对照组,而硝酸甘油用量及颈动脉IMT值低于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者血清可溶性CD105(sCD105)、P选择素及氨基末端脑钠肽前体(NT-proBNP)水平均较治疗前显著降低,同组治疗前后比较差异有统计学意义(P<0.05);治疗后,治疗组这些血清学指标显著低于对照组,两组比较差异有统计学意义(P<0.05)。结论丹蒌片联合比索洛尔治疗冠心病心绞痛疗效显著,能显著改善患者生活质量水平,改善血清学相关指标,具有一定的临床推广应用价值。
Objective To investigate the clinical efficacy of Danlou Tablets combined with bisoprolol in treatment of coronary heart disease with angina pectoris. Methods 104 Patients with coronary heart disease angina pectoris in Tianjin Third Central Hospital from February 2015 to February 2018 were randomly divided into control(52 cases) and treatment(52 cases) groups. Patients in the control group were po administered with Bisoprolol Fumarate Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Danlou Tablets on the basis of the control group, 5 tablets/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy criteria and electrocardiogram efficacy in two groups were evaluated, and the changes of ADL score, nitroglycerin dosage, carotid intima-media thickness(IMT), and serum index in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment group were 76.92% and 92.31%; and electrocardiogram efficacy in two groups were 82.69% and 96.15%, and there were differences between two groups(P < 0.05). After treatment, ADL scores in the two groups were significantly increased, but nitroglycerin dosage and IMT were significantly decreased, and there were differences in the same group(P < 0.05). After treatment, ADL scores in the treatment group were higher than that in the control group, but nitroglycerin dosage and IMT were lower than those in the control group, and there were differences between two groups(P < 0.05). After treatment, sCD105, P option element, and NT-proBNP in the two groups were significantly decreased, and there were differences in the same group(P < 0.05). After treatment, the serological indicators in the treatment group were lower than those in the control group, and there were differences between two groups(P < 0.05). Conclusion Danlou Tablets combined with bisoprolol has significant effect in treatment of coronary heart disease angina pectoris, and can significantly improve the life quality, and also can improve the serological indicators, which has a certain clinical application value.
Objective To investigate the clinical efficacy of Danlou Tablets combined with bisoprolol in treatment of coronary heart disease with angina pectoris. Methods 104 Patients with coronary heart disease angina pectoris in Tianjin Third Central Hospital from February 2015 to February 2018 were randomly divided into control(52 cases) and treatment(52 cases) groups. Patients in the control group were po administered with Bisoprolol Fumarate Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Danlou Tablets on the basis of the control group, 5 tablets/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy criteria and electrocardiogram efficacy in two groups were evaluated, and the changes of ADL score, nitroglycerin dosage, carotid intima-media thickness(IMT), and serum index in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment group were 76.92% and 92.31%; and electrocardiogram efficacy in two groups were 82.69% and 96.15%, and there were differences between two groups(P < 0.05). After treatment, ADL scores in the two groups were significantly increased, but nitroglycerin dosage and IMT were significantly decreased, and there were differences in the same group(P < 0.05). After treatment, ADL scores in the treatment group were higher than that in the control group, but nitroglycerin dosage and IMT were lower than those in the control group, and there were differences between two groups(P < 0.05). After treatment, sCD105, P option element, and NT-proBNP in the two groups were significantly decreased, and there were differences in the same group(P < 0.05). After treatment, the serological indicators in the treatment group were lower than those in the control group, and there were differences between two groups(P < 0.05). Conclusion Danlou Tablets combined with bisoprolol has significant effect in treatment of coronary heart disease angina pectoris, and can significantly improve the life quality, and also can improve the serological indicators, which has a certain clinical application value.
引文
[1]管昌益.冠心病心绞痛病因病机研究进展[J].辽宁中医杂志,1990(3):46-47.
[2]国际心脏病学会和协会及世界卫生组织临床命名标准化联合专题组.缺血性心脏病的命名及诊断标准[J].中华心血管病杂志,1981,9(1):75.
[3]皇甫丰田,唐龙骞,唐龙滨.比索洛尔的药理作用及临床应用[J].山东医药工业,2001,20(1):31-32.
[4]王富江,张鹏,于春泉,等.丹蒌片对心血管疾病的作用及相关成分的生物网络关系的探讨[J].中草药,2015,46(5):774-777.
[5]葛均波.内科学[M].北京:人民卫生出版社,2013:227-236.
[6]郑筱萸.中药新药治疗冠心病心绞痛的临床研究指导原则[M].北京:中国医药科技出版社,2002:68-73.
[7]Boyer L,Murcia A,Belzeaux R,et al.Psychometric properties of the Activities Daily Life Scale(ADL)[J].Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique,2010,36(5):408-416.
[8]刘小清.冠心病流行病学研究进展及疾病负担[J].中华心血管病杂志,2008,36(6):573-576.
[9]王丹阳,丁绍平,胡东升,等.冠心病稳定型心绞痛反复发作危险因素及防治措施[J].中西医结合心脑血管病杂志,2014,12(5):550-551.
[10]姜镜清,曾建斌.冠心病心绞痛中西医治疗研究进展[J].江西中医药,2011(3):76-78.
[11]付春茹.新型β1受体阻滞剂-比索洛尔的药理和临床应用[J].齐鲁药事,1989(4):42-45.
[12]宋梦莹,朱立光.颈动脉内中膜厚度与冠心病[J].中国医学文摘,2005(3):348-351.
[13]曹秋玫,宫海滨.可溶性CD105对评估冠心病危险程度的意义[J].中华临床医师杂志:电子版,2010,4(8):136-138.
[14]杜林林,王朝晖.P选择素在急性冠状动脉综合征中的研究进展[J].临床心血管病杂志,2003,19(7):442-444.
[15]武文君,王邦宁.冠心病患者N端脑钠肽前体水平与冠脉病变程度的相关性[J].中国老年学杂志,2014,34(14):3828-3830.
[2]国际心脏病学会和协会及世界卫生组织临床命名标准化联合专题组.缺血性心脏病的命名及诊断标准[J].中华心血管病杂志,1981,9(1):75.
[3]皇甫丰田,唐龙骞,唐龙滨.比索洛尔的药理作用及临床应用[J].山东医药工业,2001,20(1):31-32.
[4]王富江,张鹏,于春泉,等.丹蒌片对心血管疾病的作用及相关成分的生物网络关系的探讨[J].中草药,2015,46(5):774-777.
[5]葛均波.内科学[M].北京:人民卫生出版社,2013:227-236.
[6]郑筱萸.中药新药治疗冠心病心绞痛的临床研究指导原则[M].北京:中国医药科技出版社,2002:68-73.
[7]Boyer L,Murcia A,Belzeaux R,et al.Psychometric properties of the Activities Daily Life Scale(ADL)[J].Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique,2010,36(5):408-416.
[8]刘小清.冠心病流行病学研究进展及疾病负担[J].中华心血管病杂志,2008,36(6):573-576.
[9]王丹阳,丁绍平,胡东升,等.冠心病稳定型心绞痛反复发作危险因素及防治措施[J].中西医结合心脑血管病杂志,2014,12(5):550-551.
[10]姜镜清,曾建斌.冠心病心绞痛中西医治疗研究进展[J].江西中医药,2011(3):76-78.
[11]付春茹.新型β1受体阻滞剂-比索洛尔的药理和临床应用[J].齐鲁药事,1989(4):42-45.
[12]宋梦莹,朱立光.颈动脉内中膜厚度与冠心病[J].中国医学文摘,2005(3):348-351.
[13]曹秋玫,宫海滨.可溶性CD105对评估冠心病危险程度的意义[J].中华临床医师杂志:电子版,2010,4(8):136-138.
[14]杜林林,王朝晖.P选择素在急性冠状动脉综合征中的研究进展[J].临床心血管病杂志,2003,19(7):442-444.
[15]武文君,王邦宁.冠心病患者N端脑钠肽前体水平与冠脉病变程度的相关性[J].中国老年学杂志,2014,34(14):3828-3830.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |